Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis

被引:112
|
作者
Herold, Tobias [1 ,2 ,3 ]
Schneider, Stephanie [1 ]
Metzeler, Klaus H. [1 ,2 ,3 ]
Neumann, Martin [1 ,2 ,3 ,4 ]
Hartmann, Luise [1 ,2 ,3 ]
Roberts, Kathryn G. [5 ]
Konstandin, Nikola P. [1 ]
Greif, Philipp A. [1 ,2 ,3 ]
Braeundl, Kathrin [1 ,2 ,3 ]
Ksienzyk, Bianka [1 ]
Huk, Natalia [1 ]
Schneider, Irene [1 ]
Zellmeier, Evelyn [1 ]
Jurinovic, Vindi [6 ]
Mansmann, Ulrich [6 ]
Hiddemann, Wolfgang [1 ,2 ,3 ]
Mullighan, Charles G. [5 ]
Bohlander, Stefan K. [7 ]
Spiekermann, Karsten [1 ,2 ,3 ]
Hoelzer, Dieter [8 ]
Bruggemann, Monika [9 ]
Baldus, Claudia D. [2 ,3 ,4 ]
Dreyling, Martin [1 ]
Goekbuget, Nicola [8 ]
机构
[1] LMU, Univ Hosp Grosshadern, Dept Internal Med 3, Munich, Germany
[2] German Canc Consortium DKTK, Heidelberg, Germany
[3] German Canc Res Ctr, Heidelberg, Germany
[4] Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany
[5] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA
[6] LMU, Inst Med Informat Biometry & Epidemiol, Munich, Germany
[7] Univ Auckland, Dept Mol Med & Pathol, Auckland, New Zealand
[8] Goethe Univ Hosp, Dept Med 2, Frankfurt, Germany
[9] Univ Hosp Schleswig Holstein, Dept Hematol, Campus Kiel, Kiel, Germany
关键词
READ ALIGNMENT; EXPRESSION; SIGNATURE; SUBGROUP; CHILDREN; SURVIVAL; DELETION; KINASE; IKZF1; MRD;
D O I
10.3324/haematol.2015.136366
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Philadelphia-like B-cell precursor acute lymphoblastic leukemia (Ph-like ALL) is characterized by distinct genetic alterations and inferior prognosis in children and younger adults. The purpose of this study was a genetic and clinical characterization of Ph-like ALL in adults. Twenty-six (13%) of 207 adult patients (median age: 42 years) with B-cell precursor ALL (BCP-ALL) were classified as having Ph-like ALL using gene expression profiling. The frequency of Ph-like ALL was 27% among 95 BCP-ALL patients negative for BCR-ABL1 and KMT2A-rearrangements. IGH-CRLF2 rearrangements (6/16; P=0.002) and mutations in JAK2 (7/16; P<0.001) were found exclusively in the Ph-like ALL subgroup. Clinical and outcome analyses were restricted to patients treated in German Multicenter Study Group for Adult ALL (GMALL) trials 06/99 and 07/03 (n=107). The complete remission rate was 100% among both Ph-like ALL patients (n=19) and the "remaining BCP-ALL" cases (n=40), i.e. patients negative for BCR-ABL1 and KMT2A-rearrangements and the Ph-like subtype. Significantly fewer Ph-like ALL patients reached molecular complete remission (33% versus 79%; P=0.02) and had a lower probability of continuous complete remission (26% versus 60%; P=0.03) and overall survival (22% versus 64%; P=0.006) at 5 years compared to the remaining BCP-ALL patients. The profile of genetic lesions in adults with Ph-like ALL, including older adults, resembles that of pediatric Ph-like ALL and differs from the profile in the remaining BCP-ALL. Our study is the first to demonstrate that Ph-like ALL is associated with inferior outcomes in intensively treated older adult patients. Ph-like adult ALL should be recognized as a distinct, high-risk entity and further research on improved diagnostic and therapeutic approaches is needed. (NCT00199056, NCT00198991)
引用
收藏
页码:130 / 138
页数:9
相关论文
共 50 条
  • [31] Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT
    Yu Akahoshi
    Satoshi Nishiwaki
    Yasuyuki Arai
    Kaito Harada
    Yuho Najima
    Yoshinobu Kanda
    Katsuhiro Shono
    Shuichi Ota
    Takahiro Fukuda
    Naoyuki Uchida
    Souichi Shiratori
    Masatsugu Tanaka
    Junji Tanaka
    Yoshiko Atsuta
    Shinichi Kako
    Bone Marrow Transplantation, 2020, 55 : 1317 - 1325
  • [32] Predictive potential of minimal residual disease level after the first imatinib cycle on the outcome of allogeneic stem cell trasplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lee, Seok
    Kim, Yoo-Jin
    Min, Cliang-Ki
    Cho, Byung-Sik
    Kim, Sung-Yong
    Eom, Ki-Seong
    Kim, Heeje
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong-Wook
    Min, Woo-Sung
    Kim, Chun-Choo
    BLOOD, 2007, 110 (11) : 333A - 333A
  • [33] Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JS']JSHCT
    Akahoshi, Yu
    Nishiwaki, Satoshi
    Arai, Yasuyuki
    Harada, Kaito
    Najima, Yuho
    Kanda, Yoshinobu
    Shono, Katsuhiro
    Ota, Shuichi
    Fukuda, Takahiro
    Uchida, Naoyuki
    Shiratori, Souichi
    Tanaka, Masatsugu
    Tanaka, Junji
    Atsuta, Yoshiko
    Kako, Shinichi
    BONE MARROW TRANSPLANTATION, 2020, 55 (07) : 1317 - 1325
  • [34] The Extent of Minimal Residual Disease Reduction After the First 4-Week Imatinib Therapy Determines Outcome of Allogeneic Stem Cell Transplantation in Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Lee, Seok
    Kim, Yoo-Jin
    Chung, Nak-Gyun
    Lim, Jihyang
    Lee, Dong-Gun
    Kim, Hee-Je
    Min, Chang-Ki
    Lee, Jong-Wook
    Min, Woo-Sung
    Kim, Chun-Choo
    CANCER, 2009, 115 (03) : 561 - 570
  • [35] Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to the age of 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
    Geyer, Mark B.
    Ritchie, Ellen K.
    Rao, Arati, V
    Vemuri, Shreya
    Flynn, Jessica
    Hsu, Meier
    Devlin, Sean M.
    Roshal, Mikhail
    Gao, Qi
    Shukla, Madhulika
    Salcedo, Jose M.
    Maslak, Peter
    Tallman, Martin S.
    Douer, Dan
    Park, Jae H.
    HAEMATOLOGICA, 2021, 106 (08) : 2086 - 2094
  • [36] IMPACT OF ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) ON MINIMAL RESIDUAL DISEASE (MRD) AND BCR-ABL KINASE DOMAIN MUTATIONS IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH plus ALL)
    Pfeifer, H.
    Wystub, S.
    Wassmann, B.
    Brueck, P.
    Goekbuget, N.
    Wunderle, L.
    Chromik, J.
    Serve, H.
    Hoelzer, D.
    Ottmann, O. G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 368 - 368
  • [37] Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome- positive acute lymphoblastic leukemia in adults
    Harada, Kaito
    Morita-Fujita, Mari
    Fukuda, Takahiro
    Ozawa, Yukiyasu
    Doki, Noriko
    Toyosaki, Masako
    Maruyama, Yumiko
    Kanda, Yoshinobu
    Ashida, Takashi
    Eto, Tetsuya
    Takada, Satoru
    Uchida, Naoyuki
    Ichinohe, Tatsuo
    Kanda, Junya
    Onizuka, Makoto
    Atsuta, Yoshiko
    Kako, Shinichi
    Arai, Yasuyuki
    CYTOTHERAPY, 2022, 24 (09) : 954 - 961
  • [38] A NOVEL METHOD FOR MINIMAL RESIDUAL DISEASE ANALYSIS IN PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: MODIFIED BIOMED-2 POLYMERASE CHAIN REACTION FOR IMMUNOGLOBULIN HEAVY CHAIN REARRANGEMENT
    Katoh, D.
    Nakamura, M.
    Morita, M.
    Maruoka, H.
    Fujimoto, A.
    Yabushita, T.
    Shimomura, Y.
    Ono, Y.
    Hiramoto, N.
    Yoshioka, S.
    Yonetani, N.
    Matsushita, A.
    Hashimoto, H.
    Ishikawa, T.
    HAEMATOLOGICA, 2017, 102 : 660 - 660
  • [39] A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase
    Tasian, Sarah K.
    Assad, Albert
    Hunter, Deborah S.
    Du, Yining
    Loh, Mignon L.
    BLOOD, 2018, 132
  • [40] Results of the Full Pediatric, Minimal Residual Disease (MRD)-Oriented Trial LAL-RI/2008 for Adolescents and Young Adults (AYA) with Standard Risk (SR), Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL)
    Ribera, Josep-Maria
    Morgades, Mireia
    Montesinos, Pau
    Martinez-Carballeira, Daniel
    Gil, Cristina
    Barba, Pere
    Tormo, Mar
    Garcia-Boyero, Raimundo
    Guardia, Ramon
    Pedreno, Maria
    Mercadal, Santiago
    Novo, Andres
    Hernandez-Rivas, Jesus-Maria
    Bergua, Juan
    Gonzalez-Campos, Jose
    Amigo, Maria-Luz
    Cervera, Marta
    Martinez-Sanchez, Pilar
    Martino, Rodrigo
    Calbacho, Maria
    Garcia-Guinon, Antoni
    Vives, Susana
    Feliu, Evarist
    Orfao, Alberto
    BLOOD, 2017, 130